Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 20.84 USD 2.32% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Schrodinger Inc?
Write Note

Schrodinger Inc
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Schrodinger Inc
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Schrodinger Inc
NASDAQ:SDGR
Cash from Investing Activities
$65.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Cash from Investing Activities
-$546.3m
CAGR 3-Years
-2%
CAGR 5-Years
-38%
CAGR 10-Years
-9%
Inspire Medical Systems Inc
NYSE:INSP
Cash from Investing Activities
-$268.6m
CAGR 3-Years
N/A
CAGR 5-Years
-68%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Cash from Investing Activities
$31.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Cash from Investing Activities
-$51.6m
CAGR 3-Years
52%
CAGR 5-Years
3%
CAGR 10-Years
-1%
W
Waystar Holding Corp
NASDAQ:WAY
Cash from Investing Activities
-$61.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Schrodinger Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 664 full-time employees. The company went IPO on 2020-02-06. The firm operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. The Company’s physics-based software platform enables discovery of molecules for drug development and materials applications. Its software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company’s pipeline includes CDC7, Wee1, MALT1, HIF-2 alpha and SOS1/KRAS. Its CDC7 is a small molecule inhibitor for treatment of solid and liquid tumors.

SDGR Intrinsic Value
14.65 USD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Schrodinger Inc's Cash from Investing Activities?
Cash from Investing Activities
65.7m USD

Based on the financial report for Sep 30, 2024, Schrodinger Inc's Cash from Investing Activities amounts to 65.7m USD.

What is Schrodinger Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
-75%

Over the last year, the Cash from Investing Activities growth was -75%.

Back to Top